La vendita allo scoperto per MannKind dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di MannKind. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

MannKind (NASDAQ:MNKD) Azioni, Report sulle vendite allo scoperto

MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Corp

MANNKIND ORD

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.079 million which missed the analyst consensus estimate of $74.500 million by 5.93 percent. This is a 36.73 percent increase over sales of $51.253 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

MNKD

MannKind Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $70.079M Miss $74.500M Estimate

MannKind Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).
"These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options," said Michael Castagna, PharmD, Chief Executive Officer for MannKind Corporation. "We look forward to discussing the Phase 1 trial results and our proposed late-stage development program at an end of phase 1 meeting with the FDA, planned for the first half of 2025."
The key highlights of the study included:
<ul>
<li>Nintedanib DPI was shown to be safe and well tolerated in healthy volunteers with the tested doses and study duration</li>
<li>Participants did not experience typical adverse events seen with oral nintedanib; specifically, no GI or neurologic adverse events (AEs) were reported</li>
<li>Two types of AEs noted - cough and drop in FEV-1
<ul>
<li>These AEs were mild, transient, and fully recovered</li>
<li>These AEs were not dose-dependent and there was no pattern of recurrence or worsening with repeated dosing</li>
<li>No bronchospasm, wheezing, other symptoms, or change in vital signs were reported</li>
</ul>
</li>
<li>No serious adverse events or study drug discontinuation &nbsp;</li>
</ul>
The completed Phase 1 was a single-site, randomized, placebo-controlled, single- (n=24) and multiple-ascending dose (n=16) study in healthy adult (older than 40 years old) participants. The primary objective of the study was to evaluate the safety and tolerability of nintedanib DPI. The secondary study objective was to evaluate the pharmacokinetics (PK) of MNKD-201.

MannKind Completes Phase 1 Trial of Inhaled Therapy for Lung Disease, Results Show Nintedanib DPI Safe and Tolerable

MannKind Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups – one that utilized Afrezza&#xAE; (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation.
"The data from the extension phase of this study showed that more people living with T1D are able to reach target A1c levels when they remain on Afrezza (plus basal insulin) or switch to Afrezza from usual care – whether they are using multiple daily injections or pumps," said Michael Castagna, PharmD, Chief Executive Officer for MannKind Corporation. "We believe this data demonstrates to healthcare practitioners that Afrezza is an effective tool for their patients who want to improve their glycemic control."
Key Findings: There was continued improvement in the Afrezza (plus degludec)-treated group, with additional subjects achieving A1c &lt;7% at 30 weeks – a 100% increase from baseline:
&nbsp;<img src="https://ml.globenewswire.com/Resource/Download/31d76640-1047-4108-b133-36b48e91775d/image1.jpg" alt="Afrezza Group Change in HbA1c from Randomization to 30 Weeks" /> &nbsp;&nbsp;
<img src="https://ml.globenewswire.com/Resource/Download/650dc7f2-1e72-487b-9047-d0fdce0a795f/image2.jpg" alt="Afrezza Group Participants Meeting HbA1c Target" /> &nbsp;
Switching from usual care to Afrezza (plus degludec) at week-17 allowed more than double the subjects to achieve A1c &lt;7% at week-30, compared to the number at goal at week-17: &nbsp;
<img src="https://ml.globenewswire.com/Resource/Download/040e275d-bd09-4b8c-abff-4b7d76b32321/image3.jpg" alt="HbA1c Change from 17 Weeks to 30 Weeks in Usual Care-to-Afrezza Subjects" /> &nbsp;
"With the positive data received at both 17- and 30-weeks, we continue to affirm that Afrezza is an important option for adult patients managing their diabetes," said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. "We look forward to discussing more details of the 30-week study results at ATTD next March and additional conferences in 2025."
About the INHALE-3 Study The INHALE-3 study is a 17-week, randomized controlled trial with a 13-week extension conducted across 19 U.S. sites. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Subjects utilizing Afrezza (inhaled insulin) received a higher initial conversion dose than in the current U.S. product label. Both arms utilized continuous glucose monitoring to assess glucose control.
The randomized control trial (RCT) included an inhaled insulin group that began with 62 subjects at randomization and 57 at 17 weeks; the usual care group consisted of 61subjects at randomization and 58 at 17 weeks. The <a href="https://www.globenewswire.com/Tracker?data=TI60SziG0RhGZNEA5RI2SJ5ByKAZ7RbYuekeJ4VNFdyn2xJj7vBxn3F1-ieEQnO_haT6t32oFEy-0HuRk4_YqF1w6xZ4QG5Vq_qGtjFhAKH-ObJkQ_nROK_nTn749E48SDxVPIHJQZPkq3agscXzSjsIkJuglZTvKZa3fJITomoch34bhIuLQJbRMPJvbU6oq7Efby3cxy80hZr4zXFHiWXh-kDMlt4UXgABv72TMT0DNwhHeq6tMYBhdB2dWGWVGGclGx806ZRo4dt9YWUBB2AZ6kwvPEMjuxGT6xf37DT6upl-k8vHw1S3D5Xx8l6qM1eVl5_t9eDJkz41IDAiTjT7WxneHIUTh1yzQM0IGF6jYv9WW6wWDtHaEfOTPy0f">17-week results</a> previously shared that the study met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group. At 17 weeks, those who utilized Afrezza (plus basal insulin) continued with it through the extension phase, and those who were on usual care switched over to Afrezza to week 30. The extension phase started with 45 subjects from the inhaled insulin group and 43 completed the extension; the usual care-to-Afrezza group started with 49 in the extension, with 42 completing. There was no control group in the extension phase. A1c levels were obtained at baseline, 17 and 30-weeks.
<img src="https://ml.globenewswire.com/Resource/Download/72bbb5f4-f42f-4a1e-9121-3d4ff8c57790/image4.jpg" alt="Study Design INHALE-3" /> &nbsp;
More information on the INHALE-3 study is available at: <a href="https://www.globenewswire.com/Tracker?data=TRJc0HFwHf9_Kd31JrPug7XoLBMSmDbAWnUCKY-t9n7aMjvxsMn0IfLNAA99yQVgRXIIild8Mlane3Zvviwem0w91-MGoivCHDQTtc7EpuSQSWoanyhL7ZA3TB42YYCfgBJFxSIQB16YFBWsgki96R-DwMXgg29ToMS0uRhrLPd_gESnGiYIB0KOOSj8aGxdgXRWIml6z177svbbki5QOQ==">ClinicalTrials.gov(NCT05904743)</a>.

MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.50</td>
<td>$70.5K</td>
<td>38.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/04/24</td>
<td>$51.00</td>
<td>$32.5K</td>
<td>829</td>
<td>797</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$120.00</td>
<td>$34.5K</td>
<td>1.3K</td>
<td>625</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$355.00</td>
<td>$71.7K</td>
<td>16</td>
<td>505</td>
</tr>
<tr>
<td>TGTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$137.7K</td>
<td>2</td>
<td>383</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$175.00</td>
<td>$45.4K</td>
<td>513</td>
<td>382</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$45.00</td>
<td>$48.4K</td>
<td>74</td>
<td>365</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$60.00</td>
<td>$189.7K</td>
<td>4.5K</td>
<td>172</td>
</tr>
<tr>
<td>GMED</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$70.00</td>
<td>$31.6K</td>
<td>7</td>
<td>122</td>
</tr>
<tr>
<td>MNKD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.50</td>
<td>$30.0K</td>
<td>121</td>
<td>100</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 1500 contract(s) at a $32.50 strike. This particular call needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $70.5K, with a price of $47.0 per contract. There were 38163 open contracts at this strike prior to today, and today 2583 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 11 day(s) on October 4, 2024. Parties traded 500 contract(s) at a $51.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $32.5K, with a price of $65.0 per contract. There were 829 open contracts at this strike prior to today, and today 797 contract(s) were bought and sold. 
• Regarding BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we observe a call option sweep with bullish sentiment. It expires in 25 day(s) on October 18, 2024. Parties traded 150 contract(s) at a $120.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $34.5K, with a price of $230.0 per contract. There were 1345 open contracts at this strike prior to today, and today 625 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on September 27, 2024. Parties traded 239 contract(s) at a $355.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $71.7K, with a price of $300.0 per contract. There were 16 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a put option sweep that happens to be bearish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 82 contract(s) at a $40.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $137.7K, with a price of $1680.0 per contract. There were 2 open contracts at this strike prior to today, and today 383 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 329 contract(s) at a $175.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $45.4K, with a price of $138.0 per contract. There were 513 open contracts at this strike prior to today, and today 382 contract(s) were bought and sold. 
• For BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we notice a put option trade that happens to be bearish, expiring in 25 day(s) on October 18, 2024. This event was a transfer of 149 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $48.4K, with a price of $325.0 per contract. There were 74 open contracts at this strike prior to today, and today 365 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 53 day(s) on November 15, 2024. Parties traded 150 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $189.7K, with a price of $1265.0 per contract. There were 4588 open contracts at this strike prior to today, and today 172 contract(s) were bought and sold. 
• For GMED (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), we notice a put option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 102 contract(s) at a $70.00 strike. This particular put needed to be split into 31 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $310.0 per contract. There were 7 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold. 
• For MNKD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), we notice a call option sweep that happens to be bullish, expiring in 53 day(s) on November 15, 2024. This event was a transfer of 100 contract(s) at a $3.50 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $300.0 per contract. There were 121 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BHVN

BNTX

GMED

TGTX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Biotech

Health Care

General

Japan's Pharmaceuticals And Medical Devices Agency Cleared MannKind's Phase 3 Study (ICoN-1) Of Clofazimine Inhalation Suspension For Nontuberculous Mycobacterial Lung Disease. The Global Study Is Now Cleared By To Proceed In Four Countries With A Fifth (Taiwan) Expected In 4Q 2024

WIIM

MannKind shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $10 to $12.

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday.
Shares of Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) rose during Wednesday's session following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40599429/kohls-q2-earnings-profit-beat-inventory-decline-margin-growth-and-more">second-quarter financial results.</a>
The company reported a net sales decline of 4.2% Y/Y to $3.525 billion, with comparable sales for the quarter decreasing 5.1% Y/Y. Total revenue stood at $3.732 billion. The analyst consensus estimate was $3.583 billion. EPS was 59 cents, beating the analyst consensus estimate of 44 cents.
Kohl&#8217;s shares climbed 5.6% to $20.71 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Waldencast plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) jumped 41.5% to $4.0920 after the company reported second-quarter revenue growth.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) gained 17.6% to $209.40 after multiple analysts upgraded the stock and raised their price targets.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) gained 17.1% to $2.34 following second-quarter results.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 12.3% to $5.45.</li>
<li>Bioceres Crop Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) climbed 12.1% to $11.32. Bioceres Crop Solutions received green light for cultivation of Drought Tolerant HB4 Wheat in the United States.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) surged 11.3% to $58.82 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) gained 10.1% to $31.73 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) jumped 10.2% to $5.93. Oppenheimer analyst Steven Lichtman maintained MannKind with an Outperform and raised the price target from $10 to $12.</li>
<li>Westrock Coffee Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) gained 9.9% to $9.35. Westrock Coffee Company commenced warrant exchange offer and consent solicitation.</li>
<li>The Hain Celestial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) gained 10.2% to $8.93. Hain Celestial Group, on Tuesday, reported better-than-expected quarterly adjusted EPS results</li>
<li>AvePoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) jumped 8.5% to $11.69 after the company announced it commenced an offer to purchase all outstanding public warrants to purchase shares of its common stock at $2.50 per share without interest.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 8.2% to $28.04 following quarterly results.</li>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) gained 4.4% to $75.49. B of A Securities analyst Ruplu Bhattacharya upgraded Concentrix from Underperform to Neutral and raised the price target from $65 to $85.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) rose 3.3% to $49.68.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40600771/ambarella-to-rally-around-61-here-are-10-top-analyst-forecasts-for-wednesday">Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

AIXI

AMBA

AVAV

AVPT

BIOX

CHWY

CNXC

HAIN

VNET

WALD

WEST

Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday

Oppenheimer analyst Steven Lichtman maintains MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with a Outperform and raises the price target from $10 to $12.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on MannKind, Raises Price Target to $12

MannKind Q2 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $72.386M Beat $64.813M Estimate

Mannkind Announced The Launch Of An Educational Website Designed To Raise Awareness Of Nontuberculous Mycobacterial (NTM) Lung Disease

&nbsp;MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza&reg;&nbsp;(plus basal insulin) vs. usual care (defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation) utilizing a higher initial conversion dose from mealtime injectable insulin to inhaled insulin. The study, which was presented by the INHALE-3 investigational team at the American Diabetes Association&#39;s (ADA) 84th&nbsp;Scientific Sessions in Orlando, met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group.&nbsp;&nbsp;
Key sub-analysis findings included:
<ul>
<li>More subjects utilizing inhaled insulin achieved glycemic targets:
<ul>
<li>30%&nbsp;of inhaled insulin group reached &lt;7%&nbsp;(HbA1c) at 17 weeks vs.&nbsp;17%&nbsp;of the usual care group</li>
<li>21%&nbsp;of inhaled insulin group vs.&nbsp;0%&nbsp;of usual care group met A1c goal of &lt;7%&nbsp;if baseline was &gt;7%</li>
<li>24%&nbsp;of the Afrezza group and&nbsp;13%&nbsp;of the usual care group achieved TIR above&nbsp;70%&nbsp;with no increased hypoglycemia in the inhaled insulin group</li>
</ul>
</li>
<li>No difference in CGM-measured hypoglycemia between the groups</li>
<li>Study helps to establish a titrated basal-bolus ratio that is approximately 70/30 inhaled insulin to basal vs. 50/50 for usual care</li>
<li>While more people met the glycemic target of A1c (less than&nbsp;7%) with Afrezza, some subjects worsened when switching from usual care to inhaled insulin, potentially due to missing doses of inhaled insulin during the day and/or underdosing going into bedtime</li>
<li>More than&nbsp;50%&nbsp;of subjects at the end of the study expressed an interest in continuing to use Afrezza</li>
</ul>

Reported Earlier, MannKind's Inhaled Insulin Afrezza Shows Results in 17-Week Study

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with a Buy rating and announces Price Target of $8.

Initiation

Rodman & Renshaw Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $8

PULM

Pulmatrix Enters Cross License Agreement With MannKind To Use Cricket Inhalation Device For Delivery Of PUR3100 And Other Dry Powder Formulations For Neurological Diseases

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with a Overweight and maintains $6.5 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 350 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $66.263 million which beat the analyst consensus estimate of $60.490 million by 9.54 percent. This is a 63.10 percent increase over sales of $40.626 million the same period last year.

MannKind Q1 2024 Adj EPS $0.05 Beats $0.03 Estimate, Sales $66.263M Beat $60.490M Estimate

MannKind Announced The FDA Fast Track Designation For Clofazimine Inhalation Suspension (MNKD-101) For Nontuberculous Mycobacterial Lung Disease

MannKind Will Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study For Pulmonary Fibrotic Diseases

MannKind shares are trading higher after the FDA cleared the company's IND application for MNKD-10.

MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company&#39;s Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.

Government

Regulations

MannKind Announces IND Clearance From US FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

<ul>
<li>Credit and security agreement with MidCap Financial Trust repaid in full for approximately&nbsp;$31.6 million</li>
<li>Convertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately&nbsp;$8.9 million</li>
<li>Total debt reduced since December 31, 2023 is approximately&nbsp;$41.8 million</li>
</ul>

MannKind Announced That It Has Repaid In Full All Outstanding Indebtedness Under Both Its Credit And Security Agreement With Midcap Financial Trust And Its Convertible Promissory Note Issued To Mann Group LLC

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

MannKind (MNKD) announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI, or MNKD-201, for pulmonary fibrotic dise...

MannKind reports results from Phase 1 study of nintedanib DPI

MannKind Q3 2024 Earnings Preview

MannKind Non-GAAP EPS of $0.06 beats by $0.03, revenue of $70.08M misses by $4.41M

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

MannKind Corporation ( ($MNKD) ) has released its Q3 earnings. Here is a breakdown of the information MannKind Corporation presented to its investo...

MannKind Corporation Reports Strong Quarterly Growth

In a report released today, Gregory Renza from RBC Capital maintained a Hold rating on MannKind (MNKD – Research Report), with a price target of $7...

RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)

RBC Capital raised the firm's price target on MannKind (MNKD) to $7 from $5 and keeps a Sector Perform rating on the shares. The company reported a...

MannKind price target raised to $7 from $5 at RBC Capital

In a report released on November 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind (MNKD – Research Report), with a pric...

MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $12.00. The comp...

Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)

AMRN

BMRN

EYPT

GLYC

HOTH

INCY

MEIP

RVNC

Press Releases

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Management

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

MannKind to Present at Upcoming Conferences

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind to Present at 2024 UBS Healthcare Conference

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Comments

MannKind

Vendite allo scoperto

MannKind (NASDAQ:MNKD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO